Clinical trials: Acquired Immunodeficiency Syndrome (AIDS)
Chronic Disease, HIV/AIDS
Observational Pharmaco-Epidemiology Research & Analysis
Greater advances are needed in two separate but related areas in healthcare: 1) the Clinical Decision Support Systems that complement the EHR use in support of routine patient care, population management and disease management…
- Conditions
- Chronic Disease, HIV/AIDS, Liver Diseases, Inflammatory Bowel Diseases
- Trial name
- OPERA (NCT03813862)
- Testing
- Non-interventional (observational only)
- Where
- United States
- Volunteers
- 2,000,000 people, healthy volunteers welcome
- Sponsor
- Epividian
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
The goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in…
- Trial name
- NCT02016924
- Testing
- ATV, DRV, Cobicistat
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 133 people
- Sponsor
- Gilead Sciences
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
The primary objectives of Cohort 1 are to evaluate the steady state pharmacokinetics (PK) for elvitegravir (EVG) and tenofovir alafenamide (TAF) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir…
- Trial name
- NCT01854775
- Testing
- E/C/F/TAF, E/C/F/TAF (Low Dose)
- Where
- 16 sites in United States, South Africa and 3 more
- Volunteers
- 129 people
- Sponsor
- Gilead Sciences
AIDS
Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.
- Trial name
- NCT05939167
- Testing
- mesenchymal stem cell, saline
- Where
- 4 sites in China
- Volunteers
- 150 people
- Sponsor
- Cell Energy Life Sciences Group Co. LTD
AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases
Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.
This is a first in human testing of novel HIV-1 protein nanoparticles vaccine candidates, UVAX-1107 and UVAX-1197 mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants.
- Conditions
- AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases, HIV Infections
- Trial name
- NCT06541093
- Testing
- UVAX-1107, UVAX-1197
- Where
- Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Uvax Bio LLC
HIV/AIDS
Epividian / AHF: Positive Pathways - HIV Retention in Care
The primary objective of this study is to evaluate the effectiveness of a clinical decision support system (CDSS) combined with enhanced patient contact to retain HIV+ patients in care with AIDS Healthcare Foundation.
- Trial name
- NCT04147832
- Testing
- Alert to provider
- Where
- United States
- Volunteers
- 10,521 people, healthy volunteers welcome
- Sponsor
- Epividian
Kaposi's Sarcoma, HIV Positive
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
- Conditions
- Kaposi's Sarcoma, HIV Positive, AIDS
- Trial name
- NCT02029430
- Testing
- 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
HIV Coinfection, Aids/Hiv Problem
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
The primary purpose of this study is to assess the safety and efficacy of interferon-gamma by subcutaneous injection in complex treatment of patients with co-infection of HIV and pulmonary tuberculosis and to determine the…
- Conditions
- HIV Coinfection, Aids/Hiv Problem, Tuberculosis, Pulmonary, Human Immunodeficiency Virus
- Trial name
- MSPB_TB (NCT05065905)
- Testing
- Interferon-Gamma
- Where
- 2 sites in Russia
- Volunteers
- 78 people
- Sponsor
- SPP Pharmaclon Ltd.
HIV/AIDS
PlusCare: Mobile Platform to Increase Linkage to Care in Adolescents Living With HIV/AIDS
While major advancements in medical technology over the past decade have significantly improved the life expectancy of persons infected with human immunodeficiency virus (HIV), HIV-positive youth today face new barriers to the…
- Trial name
- NCT03758066
- Testing
- PlusCare
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Dimagi Inc.
HIV/AIDS
Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients
AELIX-003 study aims to investigate the safety, tolerability, immunogenicity and efficacy of a regimen containing AELIX Therapeutics' HTI T-cell vaccines and Gilead´s Toll-Like Receptor 7 (TLR7) agonist vesatolimod in…
- Trial name
- AELIX-003 (NCT04364035)
- Testing
- ChAdOx1.HTI, MVA.HTI, GS-9620
- Where
- 9 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Aelix Therapeutics
AIDS Virus, Disorder of Immune Reconstitution
Mesenchymal Stem Cells for Immune Non-responder Patients With HIV Infection
The goal of this clinical trial is to explore the effect of mesenchymal stem cell therapy on immune non-responder patients. The main questions it aims to answer are: 1.
- Trial name
- NCT05872659
- Testing
- normal saline, Mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Chronic Abnormal Immune Activation in HIV/AIDS
Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients
This is a multicenter, randomized, double-blind, dose-finding, placebo-controlled study in patients with chronic HIV infection and inadequate immune restoration treated with long-term highly active antiretroviral therapy (HAART).
- Trial name
- NCT04084444
- Testing
- T8 tablet 0.5mg, T8 tablet 1mg
- Where
- 9 sites in China
- Volunteers
- 151 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
HIV/AIDS
Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection
This is a single-center,randomized,open, single-dose, parallel-design study, which will be only enrolled Chinese healthy volunteers.
- Trial name
- NCT05206019
- Testing
- Albuvirtide
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
HIV/AIDS, Dried Blood Spot
Monitoring Of Viral Load In Decentralised Area in Vietnam
As of today, HIV-infected patients followed in decentralized area have little or even no access to viral load monitoring because laboratories able to perform this biological measurement are only in large cities, and because…
- Conditions
- HIV/AIDS, Dried Blood Spot, Viral Load
- Trial name
- MOVIDA-2 (NCT03249493)
- Testing
- Blood sample on DBS
- Where
- Vietnam
- Volunteers
- 584 people
- Sponsor
- Institut Pasteur
Acquired Immunodeficiency Syndrome, Healthy Volunteers
Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea
This study is intended to evaluate: 1. Any changes in the gut microbiome from baseline compared to end of study in both healthy (HIV-negative) subjects and HIV+ patients with or without chronic diarrhea, following one month of…
- Conditions
- Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea
- Trial name
- NCT04192487
- Testing
- Crofelemer delayed-release tablets 125mg
- Where
- 3 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Napo Pharmaceuticals, Inc.
HIV Infections, AIDS
Test Albuvirtide in Experienced Patients
The purpose of this study is to evaluate the efficacy and safety of albuvirtide combined with lopinavir-ritonavir (LPV/r) in HIV-1-infected patients who failed first-line antiretroviral therapy (ART).
- Trial name
- TALENT (NCT02369965)
- Testing
- albuvirtide, lopinavir-ritonavir, tenofovir
- Where
- 12 sites in China
- Volunteers
- 418 people
- Sponsor
- Frontier Biotechnologies Inc.
HIV/AIDS
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
The primary objectives are to assess the antiviral activity, clinical safety and tolerability parameters of albuvirtide/3BNC117 combination therapy in reducing HIV-1 viral load during the 1-week induction period treatment period.
- Trial name
- NCT04560569
- Testing
- Albuvirtide, 3BNC117 Antibody
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Frontier Biotechnologies Inc.
HIV/AIDS
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
This is a phase 2 study to evaluate the safety and tolerability of combination therapy with Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and explore the potential of viral suppression…
- Trial name
- NCT04819347
- Testing
- Albuvirtide, 3BNC117
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Frontier Biotechnologies Inc.
Lymphoma, Non-Hodgkin, HIV Infections
A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma
To estimate the response rate, response duration, clinical benefit, and toxicity of mitoguazone dihydrochloride (MGBG) in patients with AIDS-related refractory or relapsing non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00002348
- Testing
- Mitoguazone
- Where
- United States
- Sponsor
- Genzyme, a Sanofi Company